Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

cofacTau

Financiado

Cofactors at the core of tau prion behaviour

"Tau is an intrinsically disordered protein that regulates microtubule activity in neurons. Aggregation of tau into amyloid fibrils is diagnostic of several diseases, termed tauopathies, that include Alzheimer's disease. Distinct... ver más

31/08/2027

CNRS

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-02-23

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2021-STG: ERC STARTING GRANTS

I+D

Cerrada hace 3 años

0% 100%

1 Participantes

CNRS

1.45M€ | Lider

Proyectos interesantes

PGC2018-096177-B-I00 TAU MODIFICACIONES Y TAUOPATIAS 266K€ Cerrado

IJC2019-041039-I Targeting protein aggregation to treat the Tauopathies 93K€ Cerrado

RTI2018-096520-B-I00 DERIVADOS DE OXINDOL COMO LIGANDOS SELECTIVOS DE TAU. NUEVAS... 114K€ Cerrado

PGC2018-096335-B-I00 INVESTIGANDO LA AGREGACION AMILOIDE DE ALFA-SINUCLEINA EN LA... 168K€ Cerrado

PID2020-117847RB-I00 DESARROLLO DE NUEVOS INHIBIDORES PARA AMILOIDES FUNCIONALES... 169K€ Cerrado

PID2019-109276RA-I00 BASES ESTRUCTURALES DE LA TOXICIDAD DE ENSAMBLADOS TEMPRANOS... 157K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 66 meses Fecha Inicio: 2022-02-23
Fecha Fin: 2027-08-31

Presupuesto del proyecto 1M€

Descripción del proyecto "Tau is an intrinsically disordered protein that regulates microtubule activity in neurons. Aggregation of tau into amyloid fibrils is diagnostic of several diseases, termed tauopathies, that include Alzheimer's disease. Distinct amyloid aggregate structures, so-called ""strains"", are involved in different tauopathies. These assemblies can spread and recapitulate pathological phenotypes when injected in cells and animals. This is the hallmark that tau aggregates follow a prion behaviour. To date, the factors guiding the formation or propagation of specific strains are unknown. Showcasing this crucial gap in knowledge is the fact that none of the brain-extracted tau amyloid structures has been reproduced in vitro. This project intends to establish a paradigm shift for the very definition of tau strain. I propose the novel hypothesis that the co-aggregation of tau with other biomolecules such as lipids or polyanions, so-called cofactors, is a defining property of tau prion strains. To demonstrate this hypothesis, I will test that the tau-cofactor interactions (i) dictate the structure of tau aggregates, (ii) enable structure replication through seeding and (iii) dictate the neuropathology developed in cells and mice after inoculation of tau seeds. My approach is to study the pathological properties and the conformational evolution of tau aggregates in the presence of biologically-relevant cofactors possessing different physico-chemical properties. By mapping the interactions between tau and cofactors, my goal is also to establish the canonical rules governing tau structural differentiation. This proposal combines multiple methods including EPR and NMR spectroscopy, AFM-based nanospectroscopy, biochemistry, cell biology and animal histology. The proposed paradigm shift would have a very high impact in the field of tauopathies, for example by enabling accurate structure-based drug discovery, revealing new drug targets and pinpointing key deleterious metabolic pathways. "

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores